GW Pharmaceuticals plc
GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.
Contact Details
Executives
Executive Chairman
Geoffrey Guy
Managing Director
Justin Gover